Shares of TR opened at C$30.20 on Friday. Trillium Therapeutics has a 12-month low of C$28.50 and a 12-month high of C$39.45.
Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last issued its quarterly earnings results on Friday, March 9th. The company reported C($0.91) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of C($1.06) by C$0.15.
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.